Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Abstract CD20 is an established therapeutic target in B-cell malignancies. The CD20 × CD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs). Because target antigen loss is a recognized mechanism of resistance, we evaluated CD20 expression relative to c...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Stephen J. Schuster, Ling‐Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit Assouline, Nancy L. Bartlett, Lihua E. Budde, Matthew J. Matasar, Hartmut Koeppen, Emily Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Format: Artigo
Langue:anglais
Publié: 2023
Accès en ligne:https://doi.org/10.1182/blood.2023022348
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doi.org/10.1182/blood.2023022348

Documents similaires